Claims for Patent: 9,233,142

Summary for Patent: 9,233,142

Title:	Therapeutic agent for infections, and treatment method using same
Abstract:	(Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.
Inventor(s):	Masaji Okada, Yasushi Takamori, Kazuyuki Ogawa, Kinya Nagata
Assignee:	OKADA MASAJI 27% , Azbio Corp , Kinki Chuo Chest Medical Center
Application Number:	US14/292,940

Details for Patent 9,233,142

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327	January 17, 2012	9,233,142	2034-06-02

International Patent Family for US Patent 9,233,142

Country	Patent Number	Estimated Expiration
Australia	2003211274
Canada	2485882
China	101869714
China	1635902
European Patent Office	1484066
European Patent Office	2243489
European Patent Office	2532358